15.3 Hazardous Drug Exposure & Waste Disposal

Hazardous drugs as an infusion therapy safety domain

Quick Answer: Hazardous drugs (HDs) require extra controls because of cancer, reproductive, genetic, or organ toxicity risks. Core framework: know NIOSH list concepts, apply USP <800> hierarchy (engineering controls → PPE → work practices), use CSTDs when required, manage spills with HD spill kits, and segregate cytotoxic waste (trace vs bulk). Sharps still follow OSHA: puncture-resistant containers, never recap by unsafe technique.

Domain 3I.3 and related professional tasks test whether the infusion nurse can deliver therapy without becoming a second patient. Antineoplastics are the prototype, but hazardous drug concepts also include certain antivirals, hormones, and other agents on current NIOSH tables—facility HD lists and policies operationalize the national guidance.

NIOSH hazardous drug list concepts

The NIOSH List of Hazardous Drugs in Healthcare Settings groups drugs that meet criteria such as carcinogenicity, teratogenicity/developmental toxicity, reproductive toxicity, genotoxicity, organ toxicity at low doses, or structure/toxicity mimicry of existing HDs. For exam purposes:

• Not every “strong” drug is hazardous; not every hazardous drug is a classic chemo agent
• Facilities maintain HD inventories and designate receiving, storage, compounding, administration, and disposal workflows
• Table/group concepts distinguish antineoplastic HDs from non-antineoplastic HDs and from drugs with reproductive-only hazards—PPE and medical surveillance policies may differ by group
• When a stem names a drug as hazardous or antineoplastic, shift from “standard med pass” to HD precautions

You are not expected to recite the entire NIOSH table from memory, but you must know why lists exist and that policy follows the list.

USP <800>: hierarchy of controls

USP General Chapter <800> addresses handling of HDs in healthcare settings. Think in layers:

1. Engineering controls

• Containment primary engineering controls (C-PECs) such as biological safety cabinets (BSCs) or compounding aseptic containment isolators for sterile HD compounding
• Negative pressure rooms / containment secondary engineering controls (C-SECs) for compounding areas so contaminated air does not flow into clean corridors
• Appropriate ventilation and exhaust concepts for HD areas

Infusion nurses may not compound daily, but CRNI candidates should recognize that HD sterile compounding belongs in controlled environments—not at an open nursing station counter. Receiving and storage also use designated areas to limit facility contamination.

2. PPE

Typical administration-focused PPE concepts (exact ensembles are policy- and task-specific):

• Double gloves chemotherapy-rated/tested for HDs when indicated; change at timed intervals or if contaminated/torn
• Gowns that are disposable, polyethylene-coated or otherwise HD-resistant, closed front, long sleeves—remove carefully to avoid self-contamination
• Eye/face protection when splash risk exists
• Respirators when policy requires (e.g., certain spill or aerosol-generating situations)—surgical masks are not universal HD respiratory protection

Donning/doffing order matters: remove PPE so the outer contaminated surfaces do not contact skin, and dispose of PPE as HD-contaminated waste when required.

3. CSTDs and work practices

Closed system drug-transfer devices (CSTDs) mechanically prevent environmental escape of HD vapor/aerosol/liquid during transfer and administration. Many facilities require CSTDs for antineoplastic administration. Work practices include:

• Priming lines with non-HD fluid when policy allows, or priming in pharmacy with CSTD methods
• Avoiding disconnection that sprays residual HD
• Using absorbent pads, designated trays, and wipe-down procedures
• Hand hygiene after glove removal
• Restricting eating/drinking in HD handling areas

Spill kits and spill response

HD spill kits are staged where HDs are mixed, transported, or administered. General response concepts:

1. Alert others; restrict the area
2. Don appropriate HD spill PPE (often heavier than routine admin PPE)
3. Contain liquid with absorbent pads from the kit; collect glass carefully
4. Clean per kit/policy sequence (specific detergents/wipes may be required)
5. Place waste in HD-labeled containers
6. Report the spill for environmental health follow-up and medical surveillance triggers as policy directs
7. Do not use routine housekeeping methods that aerosolize powder or spread liquid into drains inappropriately

Small vs large spill definitions and who responds (unit nurse vs hazmat-type team) are facility-specific—exam focus is do not ignore, use the HD kit, protect people first.

Cytotoxic waste segregation: trace vs bulk

Hazardous drug waste is not regular trash and is not automatically the same as infectious waste alone.

Never place HD-contaminated materials in the ordinary municipal trash. Never disconnect and drain residual chemo into sinks as a disposal method. Labeling and color-coding vary by facility—follow the local scheme, but the principle of segregation is universal on the exam.

Laundry, contaminated PPE, and patient body fluids

• Contaminated gowns/gloves: dispose as HD waste when policy classifies them as such; do not take home
• Reusable textiles contaminated with HD: bag as contaminated laundry per policy—do not shake linens, which can aerosolize residue
• Patient excreta precautions: some HDs remain in urine, feces, sweat, or vomitus for a drug-specific period; use PPE for handling body fluids, double-flush toilets when policy requires, and teach patients/families precautions for the defined window
• Protect surfaces and use absorbent pads for incontinent patients receiving excreted HDs

Pregnancy and reproductive considerations for staff

Reproductive risk is a defining NIOSH concern. Policies typically allow alternative duty or reassignment options for pregnant, breastfeeding, or actively trying-to-conceive staff for certain HD tasks. Staff should know how to request accommodations without improvising unprotected exposure. Medical surveillance programs may include baseline and periodic assessments for workers who handle HDs regularly.

Exam trap: “Pregnant nurses can handle wet chemo without PPE if they are careful.” Correct concept: policy-based PPE plus optional duty restriction, never unprotected handling.

OSHA bloodborne pathogens and sharps disposal

HD practice does not replace OSHA Bloodborne Pathogens standards. Core sharps rules remain:

• Dispose of contaminated sharps immediately in puncture-resistant, labeled/color-coded sharps containers
• Place containers at point of use; do not overfill
• Never recap contaminated needles using a two-handed technique; if recapping is absolutely required in a rare protocol, use a one-handed scoop or engineered device
• Use engineered sharps injury protection devices when available
• Report needlesticks promptly for post-exposure evaluation—even with HDs, bloodborne pathogen pathways still apply, and HD exposure adds chemical risk documentation

Integrating HD safety with clinical therapy

Hazardous drug controls sit alongside antineoplastic therapy knowledge (Chapter 14 concepts) and extravasation readiness (Chapter 10). A safe chemo administration episode includes: independent double-check per policy, CSTD/PPE, line patency verification, emergency drugs available, spill kit accessible, and waste stream identified before the bag is spiked.

Master the control stack: identify HD → engineer containment → PPE + CSTD → spill readiness → segregate waste (trace vs bulk) → protect staff reproductive health → dispose of sharps the OSHA way. That stack is the spine of CRNI performance for hazardous drug exposure and waste disposal.